Premium
Generation of CD4 + cytotoxic T lymphocytes stimulated by immobilized anti‐CD3 monoclonal antibody and interleukin‐2 in cancer patients
Author(s) -
Tani Masaji,
Tammura Hiroshi,
Yamaue Hiroki,
Mizobata Shizuma,
Iwahashi Makoto,
Tsunoda Takuya,
Noguchi Kohci,
Tamai Mikiko,
Hotta Tsukasa,
Terasawa Hiroshi,
Arii Kazuo
Publication year - 1995
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910600613
Subject(s) - ctl* , cytotoxic t cell , interleukin 2 , cytotoxicity , monoclonal antibody , immunotherapy , antigen , il 2 receptor , t lymphocyte , cancer research , microbiology and biotechnology , biology , lymphokine activated killer cell , cd3 , immunology , t cell , interleukin 21 , antibody , cytokine , immune system , cd8 , in vitro , biochemistry
The proliferation of autologous tumor‐reactive cytotoxic T lymphocytes (CTL), induced by autologous mixed lymphocyte tumor‐cell culture, was remarkably enhanced by activation with immobilized anti‐CD3 monoclonal antibody (MAb) and interleukin‐2 (IL‐2), as compared with IL‐2 alone. The activated CTL exhibited high cytotoxicity against autologous tumor cells. Cytotoxicity against autologous tumor cells was inhibited by anti‐HLA‐DR MAb. In negative selection with immunomagnetic beads, cytotoxicity against autologous tumor cells was inhibited by the elimination of CD4 + cells. The major cell‐surface antigens of the activated CTL were CD3 + , CD4 + , CD25 + , CD45RO + and CD45RA ‐ , suggesting helper T cells, and the activated CTL produced IL‐2. It is concluded that the CTL activated by immobilized anti‐CD3 MAb and IL‐2 were CD4 cells that had both killer and helper functions. Our findings indicate that adoptive immunotherapy using these activated CTL would be effective in cancer patients. © 1995 Wiley‐Liss, Inc.